Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

(/sup 18/F)-N-methylspiroperidol: the radioligand of choice for PETT studies of the dopamine receptor in human brain

Journal Article · · Life Sci.; (United States)
N-Methylspiroperidol, the amide N-methyl analogue of the neuroleptic spiroperidol, was radiolabeled with fluorine-18, and its distribution in the baboon brain was studied using positron emission transaxial tomography. Stereospecific binding was demonstrated in the striatum (but not in the cerebellum) by pretreatment with (-)- or (+)-butaclamol. The kinetic distribution was similar to that of (/sup 18/F)spiroperidol, but the absolute striatal uptake (in percent of administered dose) was at least two-fold higher. Analysis of baboon blood at 10 min after injection indicated that less than half of the radioactivity in the plasma was due to unchanged radioligand. Analysis of the metabolic stability of (/sup 18/F)-N-methylspiroperidol in rat brain for 4 hr indicated that, like (/sup 18/F)spiroperidol, it is very stable to metabolic transformation in the rat central nervous system. Striatal uptake and retention in the rat was five-fold higher for (/sup 18/F)-N-methyl-spiroperidol than for (/sup 18/F)spiroperidol. The results suggest that (/sup 18/F)-N-methylspiroperidol is an ideal choice for studies of the dopamine receptor in humans. 25 references, 2 figures, 2 tables.
Research Organization:
Brookhaven National Lab., Upton, NY
DOE Contract Number:
AC02-76CH00016
OSTI ID:
6940325
Journal Information:
Life Sci.; (United States), Journal Name: Life Sci.; (United States) Vol. 36; ISSN LIFSA
Country of Publication:
United States
Language:
English